Pharma

  • US drug patent expiries to benefit Indian pharma industry September 10, 2014

    Mumbai: Expiry of drug patents in the US is great news for not only consumers but also the domestic pharmaceutical industry, where generics account for about 75 per cent of total sales, CARE Ratings said in its report released on Wednesday. Indian pharmaceutical companies have an opportunity to capitalise on the...
  • In race for bigger margins, drug makers willing to lose the India 'advantage' August 29, 2014

    Mumbai: Indian drug makers are fleeing a regulatory morass at home and moving some research and development to Europe and the United States as they try to boost margins by producing highvalue drugs. India's $15 billion a year pharma industry, the world's largest source of cheap generics, is already reeling from...
  • Andhra HC lifts stay on merger between Ranbaxy, Sun Pharma May 24, 2014

    The Andhra Pradesh High Court on Saturday vacated a status quo order it had issued earlier on Sun PharmaRanbaxy merger process, paving the way for the pharma giants becoming a single entity. While vacating the status quo, Justice G Chandraiah also disposed of the petition filed by two investors requesting the...
  • Andhra Pradesh HC verdict on Sun PharmaRanbaxy merger plea on Saturday May 23, 2014

    Hyderabad: The Andhra Pradesh High Court will on Saturday decide on the petition filed by two investors requesting it to restrain the BSE and NSE from giving any clearance to the scheme of amalgamation or merger between Sun Pharma and Ranbaxy. After hearing the arguments from the counsels of the petitioners,...
  • SC asks Andhra HC to decide on RanbaxySun Pharma merger May 21, 2014

    New Delhi: The Supreme Court on Wednesday asked the Andhra Pradesh High Court, which had passed an interim order staying the $4 billion merger of Ranbaxy with Sun Pharma, to decide the issue within two days. Hearing appeals filed by Sun Pharmaceutical, Ranbaxy Laboratories and Daiichi Sankyo Company against HC interim...
  • Cabinet clears KKR investments in two pharma companies May 13, 2014

    The government on cleared private equity major KKR's proposal to acquire stakes in two pharmaceutical companies in deals worth over Rs 1,400 crore, including 38 per cent stake buy in Gland Pharma. The two deals are estimated to be worth Rs 1,434 crore, sources said. In the first proposal, the Cabinet...
  • Make essential drugs affordable for all: Cipla May 4, 2014

    New Delhi: Amid US firms' allegations of patent norm violations against Indian pharma companies, leading domestic drug maker Cipla has said that "essential" medicines be made available to people at affordable rates and should not be sold under "monopoly". "As a scientist I believe that an inventor or innovator of a...
  • News 360: Huge turnout on first poll phase in Assam, Tripura April 7, 2014

    An estimated 72 per cent of the 64.4 lakh voters exercised their franchise peacefully in five Lok Sabha constituencies in Assam sealing the electoral fate of 51 contestants, including two union ministers in the first phase. ...
  • Sun Pharma to buy Ranbaxy in $3.2 billion deal April 7, 2014

    Tokyo: Sun Pharmaceutical Industries Ltd said it will buy generic drug maker Ranbaxy Laboratories Ltd, which has hit regulatory snags in its key US market over quality issues, in an all-share deal with total equity value of $3.2 billion. Ranbaxy, India's No.1 drugmaker by sales and 63.4 per cent held by...
  • Sensex ends 67 points up to end at record close March 5, 2014

    Mumbai: The benchmark Sensex on Wednesday extended gains by rising 67 points to end near its record close on sustained buying driven by positive global cues. Thawing of Ukraine crisis and upbeat economic data from China helped domestic markets, said traders. After gaining 263.08 points in the previous session, the Sensex...
  • IT, pharma sectors likely to be backbone of Telangana February 21, 2014

    Post bifurcation of Andhra Pradesh, the information technology and pharmaceuticals manufacturing sectors may become backbone of Telangana economy, leaving power production, ports and oil and natural gas to play a pivotal role in driving prosperity in the residuary state. With nearly 1,000 kmlong coast line, the coastal Andhra has major private...
  • Sensex rises 66 points to end at 20,376.56 February 7, 2014

    Mumbai: The Sensex on Friday rose for the fourth straight day and ended 66 points up at oneweek high levels led by gains in Tata Steel, Sun Pharma and Sesa Sterlite, amid volatility ahead of advance growth estimates for 2013/14. The index, which had gained 101 points in the previous three...
  • 19-year-old B Pharma student 'ragged' by seniors, attempts suicide September 4, 2013

    A 19-year-old B. Pharma student jumped from the third floor of her college building in Lucknow due to alleged harassment by fellow students and ragging, police said on Wednesday. Sambul Ishaq, a B Pharma student at M C Saxena Institute of Engineering and Management, was severely injured after she jumped from...
  • SC to hear PIL on the pricing of drugs in India August 5, 2013

    New Delhi: The Supreme Court on Monday will hear a PIL by the pharma companies on the pricing of medicines in India. The PIL was filed by four pharma firms who challenged the Delhi High Court's order to reduce the prices of certain medicines. These pharma companies were also asked to...
  • Italian Trentin wins Tour de France stage 14 July 13, 2013

    Lyon: Italian Matteo Trentin won the 14th stage of the Tour de France, a 191km undulating ride from Saint Pourcain sur Sioule on Saturday. The Omega PharmaQuick Step rider beat breakaway companions Michael Albasini of Switzerland and American Andrew Talansky who finished second and third. ....
  • Ranbaxy case: Should Indian patients worry over substandard drugs? June 5, 2013

    Mumbai: India exports drugs worth more than 15 billion dollars every year, a majority of which are USbound. Questions are being raised about the standards and quality, after Ranbaxy's whopping 500 million dollar settlement with the US government. The generic drugs in question were manufactured at Ranbaxy's plants in Paonta...
  • PIL in SC against Ranbaxy for manufacturing adulterated drugs June 5, 2013

    New Delhi: A Publicinterest litigation (PIL) has been moved in the Supreme Court against Ranbaxy Pharma. The PIL is seeking prosecution of all Ranbaxy directors and sealing of its manufacturing units at Paonta Sahib and Devas. This was based on Ranbaxy USA's 500 million dollar settlement with the US for...
  • Patent row: Delhi HC to hear diabetes drug case May 23, 2013

    New Delhi: The patent battle between US pharmaceuticals major Merck Sharp and Dohme (MSD) and Indian firm Glenmark Pharmaceuticals over the sale of diabetes drug Januvia comes up for hearing in the Delhi High Court on Thursday. Indian pharma company Glenmark recently came out with generic versions of Merck's type2...
  • Ranbaxy fined $ 500 mn for selling adulterated drugs May 14, 2013

    New Delhi: Generic drugmaker Ranbaxy has been fined $500 million by the US government after its subsidiary pleaded guilty to sale of adulterated drugs manufactured in India. It is the largest settlement by a generic medicine maker till date. It includes $150 million in payments for a criminal fine and...
  • Jagan's DA case: CBI may file supplementary chargesheet April 2, 2013

    Hyderabad: The CBI, probing the alleged disproportionate assets case involving YSR Congress chief YS Jaganmohan Reddy, on Monday said it could file a supplementary chargesheet in the case on Tuesday. The central agency made this submission before a special CBI court here while seeking extension of judicial remand of Jagan...
  • Investments in India by global pharma cos to continue: Vikas Dandekar April 1, 2013

    In a landmark verdict, the Supreme Court dismissed a plea by the Swiss pharmaceutical giant Novartis on Monday for a patent on its cancer drug Glivec, paving the way for more affordable lifesaving cancer drugs. How does it affect the Indian pharmaceutical industry and the global biggies who are looking...
  • Will now invest in India 'cautiously', says Novartis April 1, 2013

    Mumbai: Pharmaceutical giant Novartis on Monday termed the Supreme Court's judgement of not granting a patent to its cancer drug Glivec as "disappointing" and warned that though it will continue to introduce new products in India, it will now invest "cautiously". In a landmark verdict, the apex court dismissed the...
  • 'SC ruling discourages innovative drug discovery' April 1, 2013

    New Delhi: Swiss pharmaceutical company Novartis, which lost its battle for patent on its cancer drug Glivec in India on Monday, said the Supreme Court's ruling discourages innovative drug discovery and is a setback for patients. "Novartis has never been granted an original patent for Glivec in India. We strongly believe...
  • Novartis stock down 4.5 per cent after SC verdict April 1, 2013

    Mumbai: Shares of the Swiss pharmaceutical giant Novartis fell about 4.5 per cent on Monday after the Supreme Court of India dismissed its plea for a patent on its cancer drug, Gelvic. Shares of select Indian pharmaceutical companies rallied as the industry is set to receive a boost following the...
  • SC verdict on Novartis's cancer drug Glivec today April 1, 2013

    New Delhi: The Supreme Court on Monday is likely to pronounce its verdict in the much awaited patent case involving Glivec the anticancer drug manufactured by Swiss pharmagiant Novartis priced at a whopping Rs 1.2 lakhs for a monthly dosage. The case dates back to India's denial of...
  • SC to decide pharma patent, take up marines case April 1, 2013

    New Delhi: The Supreme Court will pronounce an important judgment on Monday on a Swiss pharma firm's plea asserting its patent over a medicine, and Tuesday take up Sterlite's plea opposing the order to shut down its plant as well as the case of the Italian marines. In a judgment that...
  • Govt approves 12 FDI proposals worth over Rs 2,609 cr March 22, 2013

    New Delhi: The government on Friday said it has approved 12 FDI proposals, including that of pharma firm Claris Otsuka, totalling over Rs 2,609 crore. The Foreign Investment Promotion Board (FIPB) headed by Economic Affairs Secretary Arvind Mayaram, also cleared the proposal of Decathlon Sports India's proposal for induction of...
  • Natco Pharma shares surge 5.3 pc after patent ruling March 5, 2013

    Mumbai: Shares in Natco Pharma Ltd surge 5.3 per cent after an Indian patent appeals board upheld on Monday a decision to allow the company to sell a generic version of Bayer AG's cancer drug Nexavar. "It would have positive earnings implication for Natco and opens up new avenues of compulsory...
  • Budget 2013 could have delivered more for healthcare February 28, 2013

    New Delhi: Healthcare and pharmaceutical industries on Thursday welcomed steps announced in the Budget to increase allotment on health and medical education. However, private players expressed concern that Finance Minister P Chidambaram could have provided support in the form of tax incentives as well. Commenting on the Budget, Apollo Hospitals Group...
  • US exports may drive growth of Indian pharma companies February 3, 2013

    Mumbai: Top Indian pharma players will continue to grow strongly at over 20 per cent in 2013, primarily led by exports to the US market, India Ratings said in its outlook for the sector. "We believe that top players of the sector will continue to grow strongly in 2013 (over...